Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prilocaine hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - - conduction anaesthesia

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prilocaine hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - - infiltration anathesia - conduction anaesthesia -sympathetic block - therapeutic a diagnostic blocks - neural therapy

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dentsply limited, united kingdom - prilocaine,felypressin - solution for injection - 30,0.54 mg/ml

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pierrel pharma s.p.a, italy - prilocaine,felypressin - solution for injection - 30,0.54 µ/ml, mg/m

Yhdysvallat - englanti - NLM (National Library of Medicine)

dentsply pharmaceutical inc. - prilocaine hydrochloride (unii: mjw015baph) (prilocaine - unii:046o35d44r), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - prilocaine hydrochloride 40 mg in 1 ml - 4% citanest plain dental (prilocaine hcl) and 4% citanest forte dental injections are indicated for the production of local anesthesia in dentistry by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia.

Yhdysvallat - englanti - NLM (National Library of Medicine)

dentsply pharmaceutical inc. - prilocaine hydrochloride (unii: mjw015baph) (prilocaine - unii:046o35d44r) - prilocaine hydrochloride 40 mg in 1 ml - 4% citanest plain dental injection, prilocaine hydrochloride injection, usp, 4% (72 mg/1.8 ml) (40 mg/ml), is indicated for the production of local anesthesia in dentistry by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - prilocaine hydrochloride -

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000 equivalent to 0.00091% w/v adrenaline acid tartrate; prilocaine hydrochloride 1%{relative} - solution for injection - 1 % - active: adrenaline acid tartrate 1:200000 equivalent to 0.00091% w/v adrenaline acid tartrate prilocaine hydrochloride 1%{relative} excipient: methyl hydroxybenzoate sodium chloride sodium hydroxide sodium metabisulfite water for injection

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000 equivalent to 0.00091% w/v adrenaline acid tartrate; prilocaine hydrochloride 2%{relative} - solution for injection - 2 % - active: adrenaline acid tartrate 1:200000 equivalent to 0.00091% w/v adrenaline acid tartrate prilocaine hydrochloride 2%{relative} excipient: methyl hydroxybenzoate sodium chloride sodium hydroxide sodium metabisulfite water for injection

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prilocaine hydrochloride, quantity: 5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - - infiltration anaesthesia - sympathetic block - therapeutic and diagnostic blocks - neural therapy